Spago Nanomedical AB (OSTO:SPAGO) Total Liabilities : kr7.47 Mil (As of Jun. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB Total Liabilities?

Spago Nanomedical AB's Total Liabilities for the quarter that ended in Jun. 2024 was kr7.47 Mil.

Spago Nanomedical AB's quarterly Total Liabilities declined from Dec. 2023 (kr11.67 Mil) to Mar. 2024 (kr7.19 Mil) but then increased from Mar. 2024 (kr7.19 Mil) to Jun. 2024 (kr7.47 Mil).

Spago Nanomedical AB's annual Total Liabilities increased from Dec. 2021 (kr6.81 Mil) to Dec. 2022 (kr8.80 Mil) and increased from Dec. 2022 (kr8.80 Mil) to Dec. 2023 (kr11.67 Mil).

Spago Nanomedical AB Total Liabilities Historical Data

The historical data trend for Spago Nanomedical AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Total Liabilities Chart

Spago Nanomedical AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2.91

3.15

6.81

8.80

11.67

Spago Nanomedical AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Liabilities	Get a 7-Day Free Trial															3.99	5.67	11.67	7.19	7.47

Spago Nanomedical AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Spago Nanomedical AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.477	+	(0	+	0.039
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.153)
	=	11.67

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	52.985	-	41.316
	=	11.67

Spago Nanomedical AB's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.135	+	(0	+	0.065
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.268)
	=	7.47

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	57.484	-	50.016
	=	7.47

Spago Nanomedical AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Spago Nanomedical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Scheelevagen 22, Lund, SWE, SE-223 63

Website

https://www.spagonanomedical.se

Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB Headlines

No Headlines